🇺🇸 FDA

Company profile · Sponsor

Tarsus

Tarsus Pharmaceuticals

TARS · NYSE biotech IRVINE, CA, USA
Pipeline
14
Drugs
1
Patents
8

Quick answer

Tarsus (TARS) is a biotech company. headquartered in IRVINE, CA, USA. listed on NYSE. NovaPharmaNews links 14 pipeline programs, 1 drug, and 8 patents to this profile..

Company facts

Ticker TARS
Exchange NYSE
Company type biotech
Headquarters IRVINE, CA, USA
SEC CIK 0001819790

Pipeline (14)

Search pipeline →

  1. TP-03

    Tarsus

    Blepharitis

    phase 3 small molecule completed

    1 trial

  2. TP-03, 0.25%

    Tarsus

    Blepharitis

    phase 3 small molecule completed

    1 trial

  3. Lotilaner Gel, 2.0%

    Tarsus

    Papulopustular Rosacea

    phase 2 small molecule completed

    1 trial

  4. Low Dose TP-05

    Tarsus

    Healthy Volunteer

    phase 2 small molecule completed

    1 trial

  5. TP-03

    Tarsus

    Meibomian Gland Dysfunction

    phase 2 small molecule completed

    1 trial

  6. TP-05 (lotilaner) Low Dose

    Tarsus

    Lyme Disease

    phase 2 small molecule active

    1 trial

  7. Vehicle of TP-03

    Tarsus

    Meibomian Gland Dysfunction

    phase 2 small molecule active

    1 trial

  8. lotilaner

    Tarsus

    Ocular Rosacea

    phase 2 small molecule active

    1 trial

  9. TP-03 (Lotilaner Ophthalmic Solution), 0.25%

    Tarsus

    Healthy

    phase 1 small molecule completed

    1 trial

  10. TP-05 (lotilaner oral capsules)

    Tarsus

    Healthy

    phase 1 small molecule completed

    1 trial

  11. TP-05 (lotilaner oral), fasted group

    Tarsus

    Healthy

    phase 1 small molecule completed

    1 trial

  12. Lotilaner ophthalmic solution, 0.25%

    Tarsus

    Demodex Blepharitis

    approved small molecule completed

    1 trial

  13. Standart medical treatment

    Tarsus

    High Intensity Interval Training

    small molecule active

    1 trial

  14. Uteratonic administration

    Tarsus

    Placenta Abruptio

    small molecule active

    1 trial

Drugs (1)

Search drugs →

  1. lotilaner

    XDEMVY

    OPHTHALMIC approved

Patents (8)

Search patents →

  1. US 12364685

    Isoxazoline parasiticide formulations

    Expires Mon Jul 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12257263

    Pharmaceutical compositions for demodex related blepharitis and eyelid crusting

    Expires Mon Mar 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12213964

    Isoxazoline parasiticide formulations

    Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12171750

    Isoxazoline parasiticide formulations and methods for treating blepharitis

    Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11752137

    Ophthalmic compositions for treating ocular Demodex using lotilaner formulations

    Expires Mon Sep 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11690826

    Methods for treating demodex blepharitis using lotilaner formulations

    Expires Mon Jun 29 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11690827

    Methods for treating ocular Demodex using lotilaner formulations

    Expires Mon Jun 29 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11197847

    Isoxazoline parasiticide formulations and methods for treating blepharitis

    Expires Mon Dec 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Tarsus?

Tarsus (TARS) is a biotech company. headquartered in IRVINE, CA, USA. listed on NYSE. NovaPharmaNews links 14 pipeline programs, 1 drug, and 8 patents to this profile..

What pipeline programs does Tarsus sponsor?

We track 14 ClinicalTrials.gov-linked programs for Tarsus, including TP-03 and 13 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Tarsus company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.